Search

Displaying results 5671 - 5680 of 8697 in total
  1. Drug

    Oxomemazine

    go.drugbank.com/drugs/DB13820
    Investigational

    Oxomemazine is a phenothiazine derivative.

    Categories: Antihistamines for Systemic Use
  2. Drug

    Xanomeline

    go.drugbank.com/drugs/DB15357
    ApprovedInvestigational

    [A264514] Xanomeline is a muscarinic agonist that was approved for the treatment of schizophrenia by the FDA in September 2024, becoming the first approved treatment for schizophrenia to target muscarinic

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  3. Drug

    Calcitonin gene-related peptide

    go.drugbank.com/drugs/DB06379
    Investigational

    As a potential drug, it has demonstrated in preclinical studies a profile that could make it an ideal anti-asthmatic drug candidate with bronchodilatory, bronchoprotecting and anti-inflammatory properties

  4. Drug

    Brensocatib

    go.drugbank.com/drugs/DB15638
    Approved

    [A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813]

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inducers
  5. Drug

    Tecadenoson

    go.drugbank.com/drugs/DB04954
    Investigational

    Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.

    Categories: Purinergic P1 Receptor Agonists
  6. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.

  7. Drug

    Tenocyclidine

    go.drugbank.com/drugs/DB01520
    IllicitInvestigational

    Tenocyclidine (TCP, thienyl cyclohexylpiperidine) is a dissociative anesthetic drug with stimulant and hallucinogenic effects. It is more potent than phencyclidine and hence, this drug was classified under the schedule 1 in 1970.

    Categories: NMDA Receptor Antagonists
  8. Drug

    Conestat alfa

    go.drugbank.com/drugs/DB09228
    Approved

    Deficiency of C1-inhibitor allows for increased plasma kallikrein activation and subsequent production of bradykinin. … Marketed as the product Ruconest (FDA), this drug is indicated for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults.

    Products: Pulver und Lösungsmittel zur Herstellung einer Injektionslösung, Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
  9. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757] … CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene.

  10. Drug

    Saprisartan

    go.drugbank.com/drugs/DB01347
    Experimental

    The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. … Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure.

    Categories: Angiotensin Receptor Antagonists, Angiotensin II receptor antagonists